Jounce Therapeutics, Inc. (JNCE) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/04/21
Jounce Therapeutics to Present Trial in Progress Posters on the Phase 1 INNATE and the Phase 2 SELECT Clinical Trials at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual MeetingGlobeNewsWire • 04/28/21
Jounce Therapeutics Appoints Dmitri Wiederschain, Ph.D., as Chief Scientific OfficerGlobeNewsWire • 04/12/21
Jounce Therapeutics Presents Preclinical Data from JTX-8064/LILRB2 Program at the 2021 American Association for Cancer Research (AACR) Virtual Annual MeetingGlobeNewsWire • 04/10/21
Conoco, Dow, Pure Storage, Signet Jewelers and More of Monday Afternoon's Analyst Calls24/7 Wall Street • 03/15/21
Jounce Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment OptionGlobeNewsWire • 03/12/21
Jounce Therapeutics to Present Preclinical Data from JTX-8064 Program at the 2021 American Association for Cancer Research Virtual (AACR) Annual MeetingGlobeNewsWire • 03/10/21
Jounce Therapeutics Announces Pricing of $56.25 Million Public Offering of Common StockGlobeNewsWire • 03/10/21
Week 10 MDA Breakout Stocks - March 2021: Short-Term Picks To Give You An EdgeSeeking Alpha • 03/06/21
Jounce Therapeutics, Inc. (JNCE) CEO Rich Murray on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/28/21
Jounce Therapeutics Reports Fourth Quarter and Full Year 2020 Financial ResultsGlobeNewsWire • 02/25/21
Jounce Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Thursday, February 25, 2021GlobeNewsWire • 02/18/21
Jounce Therapeutics Appoints Luisa Salter-Cid, Ph.D., to its Board of DirectorsGlobeNewsWire • 02/12/21
Are Options Traders Betting on a Big Move in Jounce Therapeutics (JNCE) Stock?Zacks Investment Research • 12/23/20
Jounce Therapeutics to Participate in a Fireside Chat at the Piper Sandler 32nd Annual Virtual Healthcare ConferenceGlobeNewsWire • 11/25/20
Jounce Therapeutics Receives Study May Proceed Letter from US FDA to Initiate Phase 1 Clinical Trial of JTX-8064 Targeting the LILRB2/ILT4 MechanismGlobeNewsWire • 11/16/20
Jounce Therapeutics Presents Preclinical Data from JTX-8064 Program at the Society for Immunotherapy of Cancer's (SITC) 35th Annual MeetingGlobeNewsWire • 11/11/20
Jounce Therapeutics to Participate in a Virtual Fireside Chat at Cowen 2020 IO Next SummitGlobeNewsWire • 11/09/20